Cell News and Research

RSS

Bioheart's executive management team strengthened by the inclusion of board members

Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and other cardiovascular diseases announced today that several of its Directors have joined the Company's executive management team. In addition to assuming the position of Chairman of the Company's Board of Directors, Karl E. Groth, Ph.D., became the Chief Executive Officer; Peggy A. Farley became Chief Operating Officer; and Mark P. Borman became Chief Financial Officer. Howard Leonhardt will continue as Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board. Mr. Leonhardt, the Company's founder, thus will be able to focus on enhancing the Company's existing technologies and strengthening its position as the leader within the cardiovascular arena of the stem cell therapy industry.

19 Aug 2009

Research study highlights the biological importance of Vitamin D in humans and other primates

A new study has concluded that one key part of the immune system, the ability of vitamin D to regulate anti-bactericidal proteins, is so important that is has been conserved through almost 60 million years of evolution and is shared only by primates, including humans - but no other known animal species.

19 Aug 2009

Young innovators Andrea Armani and Ellis Meng to feature in Technology Review magazine's 2009 TR35 list

The University of Southern California today announced that two faculty members from the USC Viterbi School of Engineering have been recognized by Technology Review magazine as some of the world's top innovators under the age of 35. Andrea Armani, Assistant Professor of Chemical Engineering and Materials Science, and Ellis Meng, Assistant Professor of Biomedical Engineering, will both appear on the prestigious 2009 TR35 list.

19 Aug 2009

MicroDynamics to introduce the MicroQC inspection microscope at Quality Expo

MicroDynamics will be introducing the MicroQC inspection microscope at Quality Expo. The MicroQC is a highly versatile, lightweight instrument that is extremely accurate with proven repeatable results.

19 Aug 2009

New production technology to develop vaccine for norovirus

Scientists have used a new vaccine production technology to develop a vaccine for norovirus, a dreaded cause of diarrhea and vomiting that may be the second most common viral infection in the United States after the flu. Sometimes called the "cruise ship virus," this microbe can spread like wildfire through passenger liners, schools, offices and military bases.

19 Aug 2009

Discovery of key factor that stimulates brain cancer cells to spread

Researchers funded by the National Institutes of Health have found that the activity of a protein in brain cells helps stimulate the spread of an aggressive brain cancer called glioblastoma multiforme (GBM). In a move toward therapy, the researchers showed that a small designer protein can block this activity and reduce the spreading of GBM cells grown in the laboratory.

19 Aug 2009

e-infrastructure to tackle diseases

Disease knows no borders and now researchers in Europe and the Mediterranean shoreline are using electronic infrastructures (e-Infrastructures) to coordinate and cooperate internationally.

19 Aug 2009

Custom-tailored anti-cancer drugs

Cancer remains a deadly threat despite the best efforts of science. New hopes were raised a few years ago with the discovery that the uncontrolled growth of cancer cells could be thwarted by blocking the action of proteasomes. Biochemists at the Technische Universitaet Muenchen (TUM) have illuminated a reaction pathway that does just that, in collaboration with researchers from Nereus Pharmaceuticals, based in San Diego, California. In the current issue of the Journal of Medicinal Chemistry, they report insights that could potentially lead to the development of custom-tailored anti-cancer drugs.

19 Aug 2009

FDA places Geron Corporation's IND for spinal cord injury on clinical hold

Geron Corporation (Nasdaq:GERN) today announced that its IND (Investigational New Drug application) for GRNOPC1, a cell therapy for neurologically complete, subacute spinal cord injury, has been placed on clinical hold by the FDA pending the agency’s review of new nonclinical animal study data submitted by the company. A clinical hold is an order that the FDA issues to a sponsor to delay a proposed trial or to suspend an ongoing trial.

19 Aug 2009

Aaron Whiteman to be the new CEO of GENova Biotherapeutics

GENova Biotherapeutics, Inc., ("GENova") - (OTCBB: GVBP.OB), a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, today named Aaron Whiteman as its Chief Executive Officer.

19 Aug 2009

Agito Networks announces 2009 CIO 100 award winner

Agito Networks, Inc.(TM), the company delivering innovative solutions in enterprise mobility, today announced that customer Anthony Marano Company is a recipient of the 2009 CIO 100 Award. Anthony Marano Company was distinguished for its enterprise fixed mobile convergence (eFMC) project, which is powered by Agito Networks' RoamAnywhere(TM) Mobility Router(TM).

19 Aug 2009

Aethlon Medical Chairman to present at the 14th Annual Southern California Investor Conference

Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced that it will present at today's 14th Annual Southern California Investor Conference being held at the Island Hotel in Newport Beach, California.

19 Aug 2009

Labcyte awarded 2nd Japanese patent for acoustic-based cell sorting system

Labcyte, the company that developed and commercialized the acoustic transfer of liquids today announced that the Japanese patent office has granted patent 4309131 that covers the design of an acoustic-based system that can sort cells based upon acoustic or other properties and then eject them specifically from a mixed population.

18 Aug 2009

Fractal patterns and microchannels to advance tissue engineering

Utilizing fractal patterns similar to those created by lightning strikes, Victor Ugaz, associate professor in the Artie McFerrin Department of Chemical Engineering at Texas A&M University, has created a network of microchannels that could advance the field of tissue engineering by serving as a three-dimensional vasculature for the support of larger tissue constructs, such as human organs.

18 Aug 2009

Gloucester Pharma announces FDA Advisory Committee Meeting to discuss Romidepsin NDA

Gloucester Pharmaceuticals will discuss the New Drug Application for romidepsin to treat patients with cutaneous T-cell lymphoma (CTCL) at the Oncologic Drugs Advisory Committee (ODAC) meeting on September 2, 2009.

18 Aug 2009

Mediterranean-type diet and exercise lowers Alzheimer's risk

Both being more physically active and adhering to a Mediterranean-type diet appears to be associated with reduced Alzheimer's risk, according to a new report in the August 12, 2009 issue of the Journal of the American Medical Association (JAMA).

18 Aug 2009

Disrupting the DNA-repair process

Scientists at Dana-Farber Cancer Institute have uncovered the mechanism behind a promising new approach to cancer treatment: damaging cancer cells' DNA with potent drugs while simultaneously preventing the cells from repairing themselves.

18 Aug 2009

Novel genome-analysis strategy to speed search for gene-disease links

University of Washington (UW) researchers have successfully developed a novel genome-analysis strategy for more rapid, lower cost discovery of possible gene-disease links. By saving time and lowering expenses, the approach makes it feasible for scientists to search for disease-causing genes in people with the same inherited disorder but without any family ties to each other.

18 Aug 2009

4SC starts phase 2 trial in hepatocellular carcinoma with 4SC-201 (resminostat)

4SC AG, the German drug discovery and development company, today announced the dosing of the first patient in its Phase II trial with 4SC-201 (resminostat), a pan-histone deacetylase (HDAC) inhibitor, as a new potential treatment option for patients with advanced hepatocellular carcinoma (HCC), the most frequent form of liver cancer.

18 Aug 2009

Genentech announces Phase III study results for Avastin (bevacizumab) in combination with chemo in HER2-negative breast cancer

Genentech, Inc. today announced that a Phase III study (RIBBON 2) of Avastin (bevacizumab) in combination with chemotherapy increased the time women with metastatic HER2-negative breast cancer whose initial chemotherapy had stopped working lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone.

18 Aug 2009